These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28423708)

  • 1. Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.
    Rabinowicz N; Mangala LS; Brown KR; Checa-Rodriguez C; Castiel A; Moskovich O; Zarfati G; Trakhtenbrot L; Levy-Barda A; Jiang D; Rodriguez-Aguayo C; Pradeep S; van Praag Y; Lopez-Berestein G; David A; Novikov I; Huertas P; Rottapel R; Sood AK; Izraeli S
    Oncotarget; 2017 Apr; 8(16):27380-27392. PubMed ID: 28423708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA repair and replication stress in the treatment of ovarian cancer.
    Murai J
    Int J Clin Oncol; 2017 Aug; 22(4):619-628. PubMed ID: 28643177
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer.
    Huang R; Langdon SP; Tse M; Mullen P; Um IH; Faratian D; Harrison DJ
    Oncotarget; 2016 Jan; 7(4):4695-711. PubMed ID: 26683361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A synthetic lethal screen identifies the Vitamin D receptor as a novel gemcitabine sensitizer in pancreatic cancer cells.
    Bhattacharjee V; Zhou Y; Yen TJ
    Cell Cycle; 2014; 13(24):3839-56. PubMed ID: 25558828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic effect of Chloroquine and Panobinostat in ovarian cancer through induction of DNA damage and inhibition of DNA repair.
    Ovejero-Sánchez M; González-Sarmiento R; Herrero AB
    Neoplasia; 2021 May; 23(5):515-528. PubMed ID: 33930758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MMSET/WHSC1 enhances DNA damage repair leading to an increase in resistance to chemotherapeutic agents.
    Shah MY; Martinez-Garcia E; Phillip JM; Chambliss AB; Popovic R; Ezponda T; Small EC; Will C; Phillip MP; Neri P; Bahlis NJ; Wirtz D; Licht JD
    Oncogene; 2016 Nov; 35(45):5905-5915. PubMed ID: 27109101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural maintenance of chromosomes flexible hinge domain containing 1 (SMCHD1) promotes non-homologous end joining and inhibits homologous recombination repair upon DNA damage.
    Tang M; Li Y; Zhang X; Deng T; Zhou Z; Ma W; Songyang Z
    J Biol Chem; 2014 Dec; 289(49):34024-32. PubMed ID: 25294876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Participation of the ATR/CHK1 pathway in replicative stress targeted therapy of high-grade ovarian cancer.
    Gralewska P; Gajek A; Marczak A; Rogalska A
    J Hematol Oncol; 2020 Apr; 13(1):39. PubMed ID: 32316968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of FGFR2-Signaling Attenuates a Homology-Mediated DNA Repair in GIST and Sensitizes Them to DNA-Topoisomerase II Inhibitors.
    Sergei B; Pavel D; Aigul G; Firyuza B; Ilmira N; Ilshat M; Aida A; Refat K; Natalia A; Elena S; Vera G
    Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31948066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
    Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
    Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suppression of DDX39B sensitizes ovarian cancer cells to DNA-damaging chemotherapeutic agents via destabilizing BRCA1 mRNA.
    Xu Z; Li X; Li H; Nie C; Liu W; Li S; Liu Z; Wang W; Wang J
    Oncogene; 2020 Nov; 39(47):7051-7062. PubMed ID: 32989256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of homologous recombination in the synergism between cisplatin and poly (ADP-ribose) polymerase inhibition.
    Sakogawa K; Aoki Y; Misumi K; Hamai Y; Emi M; Hihara J; Shi L; Kono K; Horikoshi Y; Sun J; Ikura T; Okada M; Tashiro S
    Cancer Sci; 2013 Dec; 104(12):1593-9. PubMed ID: 24033642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted blockade of HSP90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition.
    Gabbasov R; Benrubi ID; O'Brien SW; Krais JJ; Johnson N; Litwin S; Connolly DC
    Cancer Biol Ther; 2019; 20(7):1035-1045. PubMed ID: 30929564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.
    Ziebarth AJ; Nowsheen S; Steg AD; Shah MM; Katre AA; Dobbin ZC; Han HD; Lopez-Berestein G; Sood AK; Conner M; Yang ES; Landen CN
    Clin Cancer Res; 2013 Jan; 19(1):170-82. PubMed ID: 23147994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses.
    Muenyi CS; Pinhas AR; Fan TW; Brock GN; Helm CW; States JC
    Toxicol Sci; 2012 May; 127(1):139-49. PubMed ID: 22331493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
    Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
    Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EEPD1 Rescues Stressed Replication Forks and Maintains Genome Stability by Promoting End Resection and Homologous Recombination Repair.
    Wu Y; Lee SH; Williamson EA; Reinert BL; Cho JH; Xia F; Jaiswal AS; Srinivasan G; Patel B; Brantley A; Zhou D; Shao L; Pathak R; Hauer-Jensen M; Singh S; Kong K; Wu X; Kim HS; Beissbarth T; Gaedcke J; Burma S; Nickoloff JA; Hromas RA
    PLoS Genet; 2015 Dec; 11(12):e1005675. PubMed ID: 26684013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.